BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23906050)

  • 1. Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?
    Adamia S; Pilarski PM; Bar-Natan M; Stone RM; Griffin JD
    Curr Cancer Drug Targets; 2013 Sep; 13(7):735-48. PubMed ID: 23906050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.
    Liu J; Lin J; Huang LF; Huang B; Xu YM; Li J; Wang Y; Zhang J; Yang WM; Min QH; Wang XZ
    Tumour Biol; 2015 Sep; 36(10):8127-36. PubMed ID: 25983000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias.
    Chiarella P; Summa V; De Santis S; Signori E; Picardi E; Pesole G; Saglio G; Fazio VM
    Curr Mol Med; 2012 Jun; 12(5):547-65. PubMed ID: 22300134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
    Tortorella SM; Hung A; Karagiannis TC
    Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
    Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
    Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into biology of chronic myeloid leukemia: implications in therapy.
    Cea M; Cagnetta A; Nencioni A; Gobbi M; Patrone F
    Curr Cancer Drug Targets; 2013 Sep; 13(7):711-23. PubMed ID: 23906052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells.
    Salesse S; Dylla SJ; Verfaillie CM
    Leukemia; 2004 Apr; 18(4):727-33. PubMed ID: 14961028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.